WHO Prequalifies Rituximab Biosimilar

WHO Prequalifies Rituximab Biosimilar

The World Health Organization (WHO) has prequalified a biosimilar of version of rituximab, which is used to treat certain cancers and autoimmune diseases, created by Celltrion.  This drug therapy is the second to achieve prequalification status under the...